<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092104</url>
  </required_header>
  <id_info>
    <org_study_id>652-2-201</org_study_id>
    <nct_id>NCT01092104</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients</brief_title>
  <official_title>A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tobira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tobira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral
      activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652
      monotherapy dosed orally once daily (QD) for 10 days in HIV 1-infected, antiretroviral
      treatment-experienced, CCR5 antagonist-naïve patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 RNA Change from Baseline</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>TBR-652 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR 25 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 50 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 75 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 75 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 100 mg QD for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBR-652 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBR-652 150 mg QD for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652</intervention_name>
    <description>TBR-652 25 mg</description>
    <arm_group_label>TBR-652 25 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 Matching Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 50 mg</intervention_name>
    <description>TBR-652 50 mg QD for 10 days</description>
    <arm_group_label>TBR-652 50 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 75 mg</intervention_name>
    <description>TBR-652 75 mg QD for 10 days</description>
    <arm_group_label>TBR-652 75 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 100 mg</intervention_name>
    <description>TBR-652 100 mg QD for 10 days</description>
    <arm_group_label>TBR-652 100 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBR-652 150 mg</intervention_name>
    <description>TBR-652 150 mg QD for 10 days</description>
    <arm_group_label>TBR-652 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No clinically significant findings on Screening evaluations (clinical, laboratory, and
             ECG), which in the opinion of the Investigator would interfere with the subject's
             ability to comply with the protocol.

          2. Antiretroviral treatment-experienced; no antiretroviral therapy for at least 6 weeks
             prior to study entry.

          3. CCR5 antagonist therapy naive.

          4. CD4 cell count &gt;/= 250 cells/mm3 during Screening (within 30 days prior to first
             dose).

          5. Two separate qualifying plasma HIV 1 RNA levels &gt;/= 5,000 copies/mL within 45 days
             prior to first dose.

          6. Females who are not of reproductive potential (documented to be surgically sterile or
             postmenopausal [defined as amenorrhea ≥ 1 year and follicle stimulating hormone {FSH}
             ≥ 30 mU/mL]).

          7. Females of child-bearing potential may be enrolled following a negative serum
             pregnancy test. If participating in activity that could lead to pregnancy, males and
             females shall agree to use two forms of barrier method contraception during the trial
             and for 2 months after stopping the medication.

        Exclusion Criteria:

          1. Presence of CXCR4- or dual/mixed-tropic HIV 1 virus.

          2. Active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring
             systemic therapy during the trial).

          3. History of infection with hepatitis B or hepatitis C virus, history of cirrhosis, or
             any known active or chronic liver disease. NOTE: Hepatitis B vaccinated patients are
             eligible.

          4. Serum ALT or AST values greater than Grade 1 or bilirubin values greater than the
             upper limit of normal (ULN) at Screening.

          5. History of HIV-2.

          6. Recent history (&lt; 30 days prior to study drug administration) of clinically
             significant infection.

          7. Pregnant females or females who are breastfeeding.

          8. Treatment with immunomodulating agents (such as systemic corticosteroids,
             interleukins, interferons) or any agent with known anti-HIV activity within 30 days
             prior to study drug administration.

          9. Treatment with any vaccine within 30 days of study drug administration.

         10. A positive pre-study drug screen, including amphetamines, barbiturates, cocaine, or
             PCP.

         11. Anticipated use of antacids during the trial and/or within 7 days prior to first dose
             of study drug.

         12. Current alcohol or drug use, which in the expert judgment of the investigator, will
             interfere with the patient's ability to comply with the protocol requirements.

         13. Inability, in the opinion of the investigator, to comply with the dosing schedule and
             protocol evaluations.

         14. Use of any experimental medications within 4 weeks prior to Screening.

         15. Current (within 30 days prior to the first dose of study drug) or anticipated use of
             antimetabolites; alkylating agents; or drugs, herbal preparations, and foods
             (including grapefruit) known to affect the CYP 3A4 or CYP 2C8 enzymes or
             P-glycoprotein transporters.

         16. History of clinically significant hepatic, metabolic, endocrine, renal, hematologic,
             pulmonary, gastrointestinal, or cardiovascular disorders (including ECG
             abnormalities).

         17. Uncontrolled hypertension.

         18. Presence of a malabsorption syndrome affecting drug absorption (e.g., Crohn's disease,
             chronic pancreatitis).

         19. History of malignancy with exception of cured basal or squamous cell carcinoma of the
             skin.

         20. Receipt of radiation or cytotoxic chemotherapeutic agents and not recovered from side
             effects prior to the first dose of study medication.

         21. Subjects who have used any over-the-counter medications (including phytotherapeutic,
             herbal, or plant-derived preparations) within 14 days prior to the first dose of study
             medication, unless approved by the Investigator, or who have used St. John's wort
             within 21 days prior to the first dose of study drug. (St. John's wort is prohibited
             during the study.)

         22. History or presence of an abnormal ECG.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25. doi: 10.1097/QAI.0b013e318213c2c0.</citation>
    <PMID>21317794</PMID>
  </results_reference>
  <results_reference>
    <citation>Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 2011 Jun;55(6):2768-74. doi: 10.1128/AAC.00713-10. Epub 2011 Apr 12.</citation>
    <PMID>21486960</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <disposition_first_submitted>June 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 3, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 10, 2013</disposition_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>TAK-652</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

